Eduovisual
Cardiovascular
Cardiogenic shock: CCS-style management with vasoactives and mechanical support
— Hemodynamic signature: SBP <90 mmHg for >30 min (or vasopressors to maintain it), cardiac index <2.2 L/min/m², PCWP >15 mmHg
— Lactate >2 mmol/L, oliguria (<0.5 mL/kg/hr), altered mentation, cool/mottled extremities
— Acute MI (AMI-CS) — most common cause (~80%); LAD occlusion with large anterior STEMI is classic
— Mechanical complications post-MI: papillary muscle rupture, VSD, free wall rupture (days 3–7)
— Acute decompensated HF (chronic HFrEF tipping over)
— Fulminant myocarditis, takotsubo, peripartum cardiomyopathy
— Acute valvular catastrophe (endocarditis with regurgitation, prosthetic valve thrombosis)
— Arrhythmia-driven (VT storm, sustained bradyarrhythmia)
— RV infarct, massive PE (obstructive but managed CS-like)
— Post-MI patient who becomes hypotensive, cool, oliguric despite "adequate" volume
— Heart failure admission with rising creatinine, narrow pulse pressure, hyponatremia
— "Warm and dry" pressures normal but lactate climbing → early/pre-shock SCAI stage B
— A: At risk; B: Beginning (pre-shock, hypotension without hypoperfusion); C: Classic CS; D: Deteriorating despite initial therapy; E: Extremis/arrest
CCS pearl: On the CCS interface, the moment SBP drops with cool extremities and rising lactate post-STEMI, your next-five-minute orders are: IV access ×2, arterial line, central line, ECG, troponin, lactate, ABG, BNP, CXR, bedside echo, cardiology and cath lab consult. Do not waste a clock-tick on a fluid bolus before you've assessed volume status — most AMI-CS patients are already congested.
— Patients often describe a "crushing" feeling plus inability to lie flat
— Family may report new confusion or somnolence — this is hypoperfusion of the brain, not just "old age"
— Prolonged ischemic chest pain, prior CAD, diabetes, tobacco, family history
— STEMI with delayed presentation (>12 hours), anterior territory, prior infarct
— Post-PCI patient with recurrent pain → stent thrombosis until proven otherwise
— New harsh holosystolic murmur + thrill → VSD
— New apical systolic murmur, flash pulmonary edema → papillary muscle rupture (acute MR)
— Sudden PEA arrest, JVD, muffled tones → free wall rupture/tamponade
— Viral prodrome 1–2 weeks prior + young patient → fulminant myocarditis
— Recent emotional stressor, postmenopausal woman, apical ballooning → takotsubo
— Late pregnancy or <5 months postpartum → peripartum cardiomyopathy
— Chemotherapy (anthracyclines, trastuzumab), heavy alcohol, cocaine
— Recent initiation/uptitration of beta-blocker or non-DHP CCB in decompensated HF
— NSAIDs, negative inotropes
— Missed diuretic doses, dietary indiscretion
Key distinction: "Warm-and-wet" (congested, perfusing) versus "cold-and-wet" (congested, hypoperfused = classic CS) versus "cold-and-dry" (advanced low-output, often end-stage HF). The Forrester/Stevenson profile drives whether you reach for diuretic alone, inotrope, or both. Step 3 management: Cold-and-wet = inotrope + diuretic once MAP supports it; cold-and-dry = inotrope ± cautious fluid challenge; never blindly bolus a wet patient.
— Narrow pulse pressure (<25% of SBP) — early hallmark of low stroke volume
— Tachycardia, though elderly or beta-blocked patients may be inappropriately normocardic
— Hypoxia from pulmonary edema
— S3 gallop (volume overload, elevated LVEDP)
— New murmurs: holosystolic at LLSB → VSD; apical radiating to axilla → acute MR
— Pulsus alternans in severe LV dysfunction
— JVD elevated; Kussmaul sign suggests RV infarct or tamponade physiology
— Hepatomegaly, pulsatile liver (TR), positive hepatojugular reflux
— Bedside echo (POCUS): LV ejection fraction, RV size/function, IVC, pericardial effusion, regional wall motion, valvular catastrophe — do this within minutes
— Arterial line for continuous MAP and to draw labs
— Central venous catheter for vasopressor delivery and CVP trend
— Pulmonary artery catheter (Swan-Ganz): now back in favor for CS — measures CI, PCWP, SVR, mixed venous O2; ESCAPE trial didn't show benefit in general HF, but observational data in CS support PAC use to guide therapy and escalation
— MAP ≥65 mmHg, CI >2.2, PCWP 15–18, SvO2 >60%, lactate clearance
Board pearl: A cardiac power output (CPO) = MAP × CO / 451 of <0.6 W is the single strongest hemodynamic predictor of in-hospital mortality in CS — board questions love this number. Pair it with PAPi <1.0 to flag impending RV failure requiring RV mechanical support.
— STEMI localization: anterior (V1–V4, LAD), inferior (II/III/aVF, RCA), lateral (I/aVL/V5–V6)
— RV infarct: ST elevation in V4R — always obtain right-sided leads with inferior STEMI
— Posterior MI: ST depression V1–V3 with tall R waves → obtain V7–V9
— LBBB with Sgarbossa criteria in suspected ischemic CS
— CBC, BMP, Mg, phosphate, LFTs (shock liver: AST/ALT in thousands, INR up)
— Lactate and serial q2h to track resuscitation
— BNP/NT-proBNP — elevated supports cardiac etiology of dyspnea/shock
— ABG with mixed venous gas if Swan in place — SvO2 <60% = inadequate CO
— Coags (INR, aPTT), type and screen (anticipate cath/surgery)
— TSH (myxedema can mimic), tox screen (cocaine, methamphetamine)
— Procalcitonin/blood cultures if sepsis on the differential
Step 3 management: In any hypotensive patient with chest pain, the very first orders are simultaneous ECG + IV access + troponin + bedside echo. Do not delay cath lab activation for advanced imaging when STEMI is on the ECG — door-to-balloon ≤90 minutes still applies; in CS, immediate revascularization regardless of time since symptom onset (CULPRIT-SHOCK paradigm — culprit-only PCI preferred).
— Emergent in AMI-CS — diagnostic and therapeutic
— CULPRIT-SHOCK trial (2017): culprit-lesion-only PCI superior to immediate multivessel PCI (lower 30-day mortality/RRT)
— Staged PCI of non-culprit lesions only after stabilization
— Confirms CS hemodynamics: CI <2.2, PCWP >15, SVR elevated
— Distinguishes from distributive shock (low SVR, high CO) and hypovolemic (low PCWP)
— Guides inotrope/pressor titration and mechanical circulatory support (MCS) decisions
— Calculates CPO and PAPi for escalation triggers
— Quantifies EF, RV function, regional wall motion
— Identifies mechanical complications: VSD (color Doppler shunt), papillary muscle rupture with flail leaflet, LV thrombus, tamponade
— TEE preferred for prosthetic valves, endocarditis, aortic dissection
CCS pearl: When you "advance the clock" in CCS for a CS case, do not let the patient sit in the ED beyond ~30 minutes — order transfer to cath lab or transfer to CICU explicitly. The grader rewards rapid disposition. Key distinction: Pre-shock (SCAI B) patients without hypoperfusion get aggressive monitoring and prep for escalation but may not need pressors yet; SCAI C/D requires immediate vasoactive support and MCS evaluation.
— Stage A (At risk): large MI, decompensated HF without hypotension → monitor, treat underlying disease
— Stage B (Beginning): hypotension or tachycardia without hypoperfusion → cautious fluids if dry, early consult
— Stage C (Classic): hypoperfusion needing pharmacologic/mechanical support → vasoactives + revascularization
— Stage D (Deteriorating): failing initial therapy → escalate MCS, transfer to shock center
— Stage E (Extremis): cardiac arrest/refractory → ECMO, consider futility discussions
— Airway: intubate if work of breathing failing or altered mentation; be cautious — induction can collapse hemodynamics (use etomidate or ketamine + push-dose epinephrine ready)
— Breathing: NIPPV (BiPAP) can reduce preload/afterload in pulmonary edema before intubation
— Circulation: arterial line, central line, vasopressor (norepinephrine first-line), inotrope (dobutamine if low CO with adequate MAP)
— Disability: glucose, neuro check
— Definitive: emergent cath lab for AMI-CS; OR for mechanical complications
— Most AMI-CS patients are euvolemic or congested — avoid reflexive boluses
— RV infarct is the exception: cautious 250–500 mL crystalloid challenges with reassessment
— Need for MCS beyond IABP, refractory shock, mechanical complication, transplant/LVAD candidacy
Board pearl: Norepinephrine beats dopamine in CS — the SOAP II trial showed dopamine caused more arrhythmias and a mortality signal in the CS subgroup. Default vasopressor in CS = norepinephrine; default inotrope = dobutamine or milrinone (the latter if on chronic beta-blockade or pulmonary hypertension).
— Start 0.05 μg/kg/min, titrate to MAP ≥65
— α1 (vasoconstriction) > β1 (modest inotropy); less arrhythmogenic than dopamine/epinephrine
— β1 agonist → ↑ contractility and ↑ HR; mild β2 vasodilation (can drop SBP)
— Start 2.5–5 μg/kg/min; useful when MAP is adequate but CO low
— Tachyphylaxis after 72 hours; arrhythmogenic
— Inotrope + pulmonary and systemic vasodilator — "inodilator"
— Preferred when RV failure, pulmonary hypertension, or chronic beta-blockade
— Renally cleared — reduce dose in CKD; long half-life means hypotension is hard to reverse
— Reserved for refractory shock or peri-arrest; ↑ lactate, arrhythmias, mortality signal vs norepi+dobutamine in CS (OptimaCC trial)
— Aspirin 325 mg + P2Y12 inhibitor (ticagrelor or prasugrel) for AMI-CS
— Heparin (UFH preferred for cath/MCS) — anticoagulation for AMI and for MCS circuits
— Statin (high-intensity atorvastatin 80 mg)
— Diuretics (IV furosemide) once MAP supports — relieves congestion; can also use ultrafiltration if diuretic-resistant
— Hold beta-blockers, ACE-I/ARB, MRA acutely; reintroduce after stabilization
— Avoid nitroprusside and high-dose nitrates if hypotensive
Step 3 management: The exam-favored pairing for AMI-CS with hypotension and pulmonary edema is norepinephrine + dobutamine + emergent PCI ± IABP/Impella. CCS pearl: Always order continuous telemetry, q1h vitals, q2h lactate, strict I/Os, daily weights, and a follow-up echo at 24–48h when titrating vasoactives.
— Primary PCI is first-line regardless of symptom onset time (Class I)
— CABG if multivessel disease unsuitable for PCI or mechanical complication requiring surgery
— Fibrinolytics only if PCI unavailable within 120 minutes AND no contraindications — inferior to PCI in CS
— Culprit-only PCI per CULPRIT-SHOCK
— Intra-aortic balloon pump (IABP):
— Reduces afterload, augments diastolic coronary perfusion
— IABP-SHOCK II trial: no mortality benefit in AMI-CS → no longer routine, but still used as bridge or in mechanical complications (VSD, acute MR)
— Impella (CP, 5.5, RP):
— Axial flow pump across aortic valve; unloads LV; provides 3.5–5.5 L/min
— Use in refractory CS or as PCI support (Protected PCI)
— Complications: hemolysis, limb ischemia, bleeding, stroke
— VA-ECMO:
— Full cardiopulmonary support; for biventricular failure, refractory CS, peri-arrest (ECPR)
— Risk: LV distension — often need LV venting with IABP or Impella ("ECPELLA")
— Complications: bleeding, limb ischemia, stroke, Harlequin/North-South syndrome (upper-body hypoxia in peripheral femoral VA-ECMO with recovering native LV)
— TandemHeart: trans-septal LA-to-femoral artery pump
— Durable LVAD or heart transplant: for select patients not recovering — bridge-to-decision strategy
— VSD: surgical or percutaneous closure (high mortality if early)
— Papillary muscle rupture: emergent mitral valve replacement
— Free wall rupture: emergent surgical repair
Board pearl: DanGer Shock trial (2024) showed Impella CP reduced 6-month mortality in STEMI-CS vs standard care — a paradigm shift. CCS pearl: Order transfer to a shock/MCS-capable center if your facility lacks Impella/ECMO; document the indication.
— Higher baseline mortality in CS, but age alone is not a contraindication to PCI or MCS
— SHOCK trial subgroup: benefit of early revascularization in <75; for ≥75, individualize (frailty, functional status, goals of care)
— Beware of atypical presentations: confusion, falls, weakness instead of chest pain
— Polypharmacy: beta-blockers, CCBs may blunt tachycardic response
— Higher bleeding risk on dual antiplatelet + anticoagulation — consider radial access, shorter DAPT duration discussions post-stabilization
— Contrast-induced nephropathy risk in PCI — do not withhold lifesaving angiography; minimize contrast, use isotonic saline pre/post
— Milrinone is renally cleared — reduce dose or avoid in CKD/AKI
— Dobutamine and norepinephrine are not significantly renally cleared
— Loop diuretics: higher doses needed in CKD; consider CRRT for diuretic-resistant volume overload with hemodynamic instability
— Hold ACE-I/ARB/MRA in AKI; reintroduce carefully once stable
— Transaminases in thousands + INR up = ischemic hepatitis from low CO — resolves with restored perfusion
— Avoid hepatotoxic drugs; adjust amiodarone, lidocaine dosing
— Coagulopathy increases procedural bleeding — correct only for active bleeding or pre-procedure
Step 3 management: In an 82-year-old with anterior STEMI and CS, the right answer remains emergent PCI + norepinephrine + dobutamine, with early goals-of-care conversation documented. Key distinction: Functional status before admission predicts post-CS recovery more than chronologic age — get a collateral history from family.
— New HF with LVEF <45% in last month of pregnancy or up to 5 months postpartum, without other cause
— Risk factors: multiparity, advanced maternal age, preeclampsia, African ancestry
— Treatment: standard HF therapy except in pregnancy — avoid ACE-I/ARB/ARNI/MRA (teratogenic); use hydralazine + nitrates + beta-blocker (metoprolol or carvedilol)
— Bromocriptine (prolactin inhibitor) — emerging evidence; controversial, suppresses lactation
— Anticoagulation if EF <35% (high thrombotic risk peripartum)
— Future pregnancies: high recurrence risk if EF doesn't normalize
— Spontaneous coronary artery dissection (SCAD) — most common cause of pregnancy-associated MI; conservative management often preferred over PCI
— Amniotic fluid embolism, pulmonary embolism
— Severe preeclampsia/eclampsia with cardiac dysfunction
— Causes: congenital heart disease, viral myocarditis, arrhythmias, sepsis with cardiac dysfunction
— Weight-based dosing; milrinone and epinephrine commonly used
— ECMO is established rescue therapy
— Think myocarditis, cocaine/methamphetamine, SCAD, congenital coronary anomalies, familial cardiomyopathy
— Always send toxicology, viral studies, consider cardiac MRI after stabilization
— Genetic counseling for familial DCM
Board pearl: A 32-year-old G3P3 woman 2 months postpartum with new dyspnea, EF 25%, pulmonary edema = PPCM until proven otherwise — give furosemide + hydralazine + metoprolol + anticoagulation; ACE-I only after breastfeeding stops or use enalapril/captopril (compatible with breastfeeding) if benefit outweighs risk.
— Papillary muscle rupture → acute severe MR, flash pulmonary edema, new apical murmur → emergent surgery
— Ventricular septal rupture → new harsh holosystolic murmur with thrill, RV failure, step-up in O2 sat on RHC → surgical/percutaneous closure
— Free wall rupture → tamponade, PEA arrest → emergent pericardiocentesis + surgery; mortality >90%
— LV pseudoaneurysm → contained rupture; surgical repair
— VT/VF in ischemia → defibrillation, amiodarone, lidocaine, urgent revascularization
— AV block in inferior MI → atropine, transcutaneous/transvenous pacing
— Electrical storm may require sedation, beta-blockade, stellate ganglion block, VA-ECMO
— AKI (cardiorenal syndrome type 1) — common; may require CRRT
— Ischemic hepatitis (shock liver) — transaminases >1000, resolves with reperfusion
— Mesenteric ischemia — out-of-proportion abdominal pain, rising lactate
— Stroke — embolic from LV thrombus or MCS-related
— Anoxic brain injury post-arrest — TTM (targeted temperature management 32–36°C × 24h)
— Bleeding, hemolysis (Impella, ECMO), limb ischemia (femoral cannulation), DIC, infection, Harlequin syndrome (VA-ECMO), aortic insufficiency progression
CCS pearl: When a post-MI patient suddenly worsens with new murmur and hypotension on day 4, immediately order STAT echo, surgery consult, IABP placement, and transfer to OR — don't waste a clock tick on more diuretics. Key distinction: New systolic murmur + step-up on Swan = VSD; new murmur + flash pulmonary edema + no step-up = papillary muscle rupture.
— Interventional cardiology for emergent cath
— CT surgery for mechanical complications or MCS implantation
— Advanced HF/transplant cardiology for refractory CS or pre-shock with worsening trajectory
— Critical care for ventilator, sedation, CRRT
— Palliative care early — for symptom management and goals-of-care, not just end-of-life
— Rising lactate despite norepi + dobutamine
— CPO <0.6 W, PAPi <1.0
— Worsening end-organ function (oliguria, encephalopathy, rising LFTs)
— Need for >2 vasoactive agents
— Recurrent arrhythmias
— Cardiac cath lab with 24/7 capability
— Impella, ECMO, or surgical backup
— Advanced HF program for LVAD/transplant evaluation
— Use ground or air transport with MCS-trained team — Impella and ECMO can be transported
— Single page activates IC, CT surgery, HF, CICU, perfusionist
— Centers with shock teams show mortality reduction (~20–30% improvement)
— Update q4–6h or with major change; document goals of care; involve surrogate decision-maker
Step 3 management: Refractory CS with rising lactate on norepi + dobutamine at a non-MCS center = call shock team, prepare for transfer, start Impella or VA-ECMO if available, do not delay. CCS pearl: Document "transferred to tertiary CICU for advanced mechanical circulatory support evaluation" — this is the kind of disposition phrasing the case rewards.
— Chronic LV dysfunction tipped over by ischemia, arrhythmia, medication non-adherence, dietary indiscretion, infection
— Treatment overlaps but revascularization not the priority — diuresis + inotrope + cause-directed care
— Young patient, viral prodrome, rapid biventricular failure, often dramatic recovery with support
— Cardiac MRI, endomyocardial biopsy if giant cell suspected (steroids + immunosuppression)
— VA-ECMO often used as bridge to recovery (excellent prognosis if survives acute phase)
— Postmenopausal woman + emotional/physical trigger; apical ballooning; troponin mildly elevated
— Treatment: supportive; avoid inotropes if LV outflow tract obstruction present (paradoxical worsening); use phenylephrine + beta-blocker instead
— Usually resolves in 4–8 weeks
— Endocarditis with leaflet destruction → acute MR/AR
— Prosthetic valve thrombosis → fibrinolytics or emergent surgery
— Aortic dissection extending to coronaries or aortic valve
— VT storm, sustained SVT, complete heart block — restore rhythm and rate first
— Tachycardia-induced cardiomyopathy
— Technically obstructive, but presents similarly; pulsus paradoxus, equalized diastolic pressures
— Pericardiocentesis is curative
— Avoid inotropes/diuretics; give fluids + phenylephrine + beta-blocker
Key distinction: Takotsubo and HCM with obstruction are the two "do-not-give-dobutamine" CS mimics — inotropes worsen LVOT obstruction. Always check for systolic anterior motion (SAM) on echo before reflexively starting dobutamine.
— Warm extremities, low SVR, high CO (early), wide pulse pressure
— Treatment: fluids first, then norepinephrine, source control
— Mixed septic + cardiogenic ("septic cardiomyopathy") is common — echo reveals depressed EF
— Hemorrhage (GI, trauma, ruptured AAA), severe dehydration
— Low CVP, low PCWP, high SVR, narrow pulse pressure
— Treatment: blood products, fluids, source control; avoid pressors before volume
— Massive PE: sudden hypoxia, RV strain on echo, elevated D-dimer, CT-PA confirms; treat with thrombolytics (tPA) or thrombectomy
— Tamponade: muffled tones, JVD, pulsus paradoxus, echo shows effusion with RV diastolic collapse → pericardiocentesis
— Tension pneumothorax: absent breath sounds, tracheal deviation, hyperresonance → needle decompression
— AMI + sepsis (e.g., pneumonia precipitating NSTEMI)
— CS with secondary SIRS from prolonged hypoperfusion → low SVR + low CO ("vasoplegic CS")
— Requires combination therapy: pressors + inotropes + antibiotics
— Refractory hypotension unresponsive to pressors; history of steroid use or autoimmune disease
— Stress-dose hydrocortisone 100 mg IV
Board pearl: The fastest bedside way to distinguish CS from other shocks is POCUS: depressed LV + dilated IVC = cardiogenic; collapsing IVC + hyperdynamic LV = hypovolemic/distributive; dilated RV with septal flattening = PE; pericardial effusion with RV collapse = tamponade. Step 3 management: Order bedside echo as part of initial undifferentiated shock workup — it changes management within minutes.
— Dual antiplatelet therapy: aspirin 81 mg indefinitely + P2Y12 inhibitor (ticagrelor or prasugrel) for 12 months (longer if high ischemic risk, shorter if high bleed risk)
— High-intensity statin: atorvastatin 80 mg or rosuvastatin 40 mg — LDL goal <55 mg/dL post-MI
— Beta-blocker: carvedilol, metoprolol succinate, or bisoprolol — titrate up after hemodynamic stability
— ACE-I or ARB: lisinopril, ramipril, or losartan — start low, titrate
— MRA: spironolactone or eplerenone if EF ≤40% with HF symptoms or diabetes
— SGLT2 inhibitor: dapagliflozin or empagliflozin — class I for HFrEF regardless of diabetes
— ARNI (sacubitril/valsartan): replaces ACE-I/ARB in HFrEF; wait 36h after ACE-I before starting
— Loop diuretic PRN for congestion
— GDMT for HFrEF (BB + ACE-I/ARB/ARNI + MRA + SGLT2i) until recovery
— Reassess EF at 3–6 months; if recovered, individualize whether to continue therapy
— Wait 40 days post-MI and 3 months post-revascularization to reassess EF
— If EF ≤35% with NYHA II–III on optimal GDMT → primary prevention ICD
— Wearable defibrillator (LifeVest) bridge during waiting period
— Smoking cessation (varenicline, bupropion, NRT), Mediterranean diet, BP <130/80, A1c <7%, weight loss
Step 3 management: Every post-CS patient leaves with aspirin, P2Y12, statin, BB, ACE-I/ARB, MRA, SGLT2i, loop diuretic PRN, cardiac rehab referral, and 1–2 week follow-up.
— 7–14 days: primary care or HF clinic visit — medication reconciliation, symptom check, weight, BP, BMP (K+, creatinine on ACE-I/ARB/MRA)
— 30 days: cardiology follow-up — uptitrate GDMT, review adherence
— 3 months: repeat echo to reassess EF and guide ICD decision
— 6 months and annually: ongoing GDMT optimization, risk factor control
— Daily weights at home — call clinic if gain >2 lb/day or >5 lb/week
— BP and HR log
— Symptoms: dyspnea, orthopnea, PND, edema, fatigue, palpitations
— Labs: BMP at 1–2 weeks after starting/uptitrating ACE-I/ARB/MRA/diuretic; A1c, lipids q3–6mo initially
— 36 sessions over 12 weeks, supervised exercise + education + risk factor modification
— Insurance-covered post-MI, post-PCI, post-CABG, HFrEF
— Reduces mortality, readmissions, improves QoL
— Driving restrictions: post-MI without ICD = 1 week (private) / 1 month (commercial); post-ICD shock-eligible = 1 week if primary prevention, longer if secondary
— Sexual activity: generally safe after stable exercise tolerance (~3–5 METs, e.g., 2 flights of stairs); avoid PDE5 inhibitors with nitrates
— Travel: avoid air travel for 2 weeks post-MI; longer if complicated
— Vaccinations: annual flu, pneumococcal, COVID, RSV (age-appropriate)
— Depression screening (PHQ-9): prevalence 20–30% post-CS; treat with SSRI (sertraline preferred)
Board pearl: Cardiac rehab is one of the most underutilized Class I interventions — referring at discharge dramatically improves uptake. CCS pearl: Always order "cardiac rehabilitation referral" and "follow-up in 7–14 days" on the discharge order set.
— Patients are often encephalopathic, intubated, or peri-arrest — cannot consent
— Use surrogate decision-maker hierarchy (spouse → adult children → parents → siblings, varies by state)
— Emergency exception applies for lifesaving PCI/MCS — document the emergency
— When time allows, discuss MCS goals: bridge to recovery, bridge to decision, bridge to durable LVAD/transplant, or destination — patients and families must understand these
— Early palliative consult is not giving up — it improves symptom control and family support
— Discuss ICD deactivation in patients with advanced HF transitioning to comfort care — ICD shocks at end of life are distressing and inappropriate
— DNR status does not preclude PCI or vasoactives unless explicitly stated; clarify "DNR but full treatment otherwise" vs comfort-focused
— Ethically equivalent to withdrawal of other life-sustaining therapy
— Requires consensus among team, surrogate, and clarity of patient's prior wishes
— Document discussions thoroughly
— Medication reconciliation is critical — CS patients leave on 8–10 new medications; errors in beta-blocker dosing, anticoagulation, and diuretics drive readmissions
— Warm handoff between CICU → step-down → floor → outpatient
— Teach-back method for discharge education (weight, symptoms, when to call)
— 30-day readmission penalties (CMS HRRP) apply to HF — discharge planning matters financially and clinically
Step 3 management: Document a goals-of-care conversation within 24–48 hours of CICU admission, identify the surrogate, and address ICD/MCS withdrawal contingencies proactively.
Board pearl: If the stem says "anterior STEMI + hypotension + clear lungs + elevated JVP" — think RV infarct extending from inferior MI or tamponade from free wall rupture, NOT volume depletion. Order right-sided ECG (V4R) and bedside echo immediately.
Key distinction: Questions test the trigger to escalate (vasoactive failure, rising lactate, CPO <0.6, PAPi <1.0) more than the initial choice of norepi/dobutamine — recognize the deteriorating patient and act.
Cardiogenic shock is end-organ hypoperfusion from primary pump failure — most commonly from acute MI — and is managed by simultaneous norepinephrine + dobutamine, emergent culprit-only PCI when ischemic, and stage-appropriate escalation through IABP, Impella, and VA-ECMO at a shock-team center, followed by full guideline-directed medical therapy and cardiac rehabilitation.
Board pearl: The Step 3 winning move in any CS vignette is simultaneous resuscitation and definitive therapy — norepinephrine + dobutamine + cath lab activation in the same breath, never sequentially.